Literature DB >> 15802113

[Indication of bone densitometry in women over 40 years of age].

Mc Moreno Girao1, F Centelles Mañosa, E Jovell Fernández.   

Abstract

OBJECTIVE: To evaluate the indication of bone densitometry (BD) and to know the prevalence of risk factors (FR) for osteoporotic fracture in primary care.
DESIGN: Cross-sectional, descriptive study.
SETTING: Urban centre of health of Terrassa, Barcelona (52.000 h). PARTICIPANTS: Women over 40 years old than went to urgencies of the centre selected by consecutive sampling stratified by age (n=416). MAIN MEASUREMENTS: Registry of FR for osteoporotic fracture according to the criteria of the Agència d'Avaluació de Tecnologies Mèdiques (AATM), hygienic-dietetic recommendations received and made BDs.
RESULTS: The average age was of 60+/-13 years. The FR for osteoporotic fracture more prevalence were: low calcium intake (32.1%), increased age (27.5%), no lactation (24.9%), and precocious menopause (16.4%). They had received dietetic recommendations 35.7%, of exercise 65.5% and solar exhibition 18.1%. Of the 177 (42.7%) cases in that the BD was indicated only it made in 45 (25.4%) and of 237 (57.3%) without indication of BD they were made 41 (17.2%). To have made BD is related of statistically significant way to antecedent of osteoporotic fracture (P<.001) and to iatrogenic menopause (P<.001). The 41.2% of the BDs were asked for by the primary care physician, the 34.1% by the rheumatologist and the 16.5% by the gynaecologist. The indication of BD varies between the different scientific societies: AATM 42.7%, semFYC 45.7%, FORE 49.8%, SER 61.1%, and NOF 64.3%.
CONCLUSIONS: Although FR of prevalence osteoporosis are most modifiable from primary care, a low degree of advice exists on healthful habits of life. A low accomplishment of BDs is detected and half is not adapted its indications according to the criteria of the AATM. There is great variability in the indication of BD between the different scientific societies.

Entities:  

Mesh:

Year:  2005        PMID: 15802113      PMCID: PMC7684435          DOI: 10.1157/13072790

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  6 in total

1.  [Risk factors related to osteoporosis and age of onset of menopause in the general population].

Authors:  M Ceinos Arcones; E Acosta Estévez; C Martín Perpiñán; L Yeves Yeves; J M Atienza López; M A González Galán
Journal:  Aten Primaria       Date:  1999 Jul-Aug       Impact factor: 1.137

2.  [Screening for bone disease risk with clinical factors in women after physiologic menopause].

Authors:  A Díez; J Puig; X Nogués; H Knobel; S Mínguez; A Supervía; L Mellibovsky; M D Arnau; R Carreras; S Serrano; J Aubía
Journal:  Med Clin (Barc)       Date:  1998-02-07       Impact factor: 1.725

3.  [Prevalence of osteoporosis assessed by densitometry in the Spanish female population].

Authors:  M Díaz Curiel; J J García; J L Carrasco; J Honorato; R Pérez Cano; A Rapado; C Alvarez Sanz
Journal:  Med Clin (Barc)       Date:  2001-01-27       Impact factor: 1.725

4.  [Diagnosing osteoporosis in primary care in Spain (ABOPAP 2000 study)].

Authors:  R Aragonès Forès; P Orozco López
Journal:  Aten Primaria       Date:  2002-10-15       Impact factor: 1.137

5.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18

6.  [Prevalence study of symptoms and risk factors associated with climacteric].

Authors:  M Rollán Landeras; M J Bedoya Frutos; M L Illescas Sánchez; R Martín Masedo
Journal:  Aten Primaria       Date:  1995-10-15       Impact factor: 1.137

  6 in total
  1 in total

1.  Screening for osteoporosis among post-menopausal women in community pharmacy.

Authors:  Damià Barris Blundell; Carmen Rodríguez Zarzuelo; Belén Sabio Sánchez; José Luis Gutiérrez Álvarez; Elena Navarro Visa; Oscar Muñoz Valdés; Belén Garrido Jiménez; Rocío Sánchez Gómez
Journal:  Pharm Pract (Granada)       Date:  2006-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.